Printer Friendly

PsychoGenics receives licenses from Mayo Clinic and TET Systems for rTg4510 tauopathy mouse model.

M2 EQUITYBITES-February 4, 2014-PsychoGenics receives licenses from Mayo Clinic and TET Systems for rTg4510 tauopathy mouse model

(C)2014 M2 COMMUNICATIONS http://www.m2.com

PsychoGenics, a provider of a range of standard and customised preclinical services, has received licenses from Mayo Clinic and TET Systems for the rTg4510 tauopathy mouse model, it was reported yesterday.

The rTg4510 mouse model expresses the P301L mutation in the tau gene associated with frontotemporal dementia and Parkinsonism linked to chromosome 17. Transgene expression in this model is made through the tetracycline-operon responsive element, which is licensed from TET Systems, and is reversibly suppressed after treatment with doxycycline.

Dr Karen K Hsiao Ashe, Dr Jada Lewis and Dr Michael Hutton have developed the rTg4510 mice that exhibit many salient characteristics of hereditary human dementia in an age-dependent manner covering cognitive impairment, motor deficits, the presence of neurofibrillary tangles and neuronal loss in the forebrain.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 4, 2014
Words:161
Previous Article:Systemair buys Menerga sales firms in Switzerland, Germany.
Next Article:Sagent Pharmaceuticals opens National Research Centre in Chengdu, China.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters